Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904057 | 0.86 | KDM4E (0.43) | THRBPGAM1KDM4EMAPTALOX5AP | |
| SCHEMBL2906943 | 0.86 | KDM4E (0.43) | THRBPGAM1KDM4EMAPTALOX5AP | |
| SCHEMBL13568738 | 0.77 | PKLR (0.44) | PGAM1KDM4EMAPTPTPN1PKLR | |
| SCHEMBL2903786 | 0.77 | THRB (0.40) | THRBPGAM1THRA | |
| SCHEMBL2901427 | 0.76 | SOAT1 (0.45) | THRBPGAM1THRAKDM4EMAPT | |
| SCHEMBL2906203 | 0.74 | TDP1 (0.40) | PGAM1KDM4EMAPTPTPN1PKLR | |
| SCHEMBL9555081 | 0.74 | TRPV1 (0.48) | THRBTHRASERPINE1 | |
| SCHEMBL9761319 | 0.74 | ALDH1A1 (0.46) | THRBTHRAKDM4EMAPTPARG | |
| SCHEMBL2908399 | 0.73 | SOAT1 (0.45) | KDM4EMAPT | |
| SCHEMBL2901189 | 0.73 | SOAT1 (0.45) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9039946-B2 | Reversibly thermochromic compositions | BASF SE (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9039946-B2 | Reversibly thermochromic compositions | BASF SE (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-1888705-B1 | Reversibly thermochromic compositions | BASF SE (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090302284-A1 | Reversibly Thermochromic Compositions | CIBA CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1888705-A1 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | Ciba Specialty Chemicals Holding, Inc. (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006131465-A1 | REVERSIBLY THERMOCHROMIC COMPOSITIONS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090302284-A1 | Reversibly Thermochromic Compositions | DHCR7, NES, DUT | THRB 2800/4885PGAM1 3060/4885THRA 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.